← All organizations

Silverback Therapeutics

For profitWebsite ↗

Also known as: Silverback Therapeutics | Silverback Therapeutics, Inc.

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 2

First clinical trial

Last known activity

Mar 31, 2022

Acquired by ARS Pharmaceuticals, Inc. on Jul 25, 2022

Timeline

2010s

Jun 1, 2016
Silverback Therapeutics— Founded

2020s

Jul 25, 2022
ARS Pharmaceuticals, Inc.— Acquired By

Drugs by trial phase (7 distinct, 3 trials)

Phase 2 (7 own, 0 via acquisition)

Indications

Studied for

Neoplasms

Recent trials (6)

NCT05234606Lead sponsorPhase 1/Phase 2Mar 31, 2022
NCT05234606Study directorPhase 1/Phase 2Mar 31, 2022
NCT05091528Lead sponsorPhase 1/Phase 2Dec 31, 2021
NCT05091528Study directorPhase 1/Phase 2Dec 31, 2021
NCT04460456Study directorPhase 1Jul 27, 2020
NCT04460456Lead sponsorPhase 1Jul 27, 2020

Details

Founded: Seattle, WA, US Jun 1, 2016
Last known activity: Mar 31, 2022